Get the Stockscreener App
61.23
1.76%
-1.10
Cytokinetics Inc stock is traded at $61.23, with a volume of 985.43K.
It is down -1.76% in the last 24 hours and down -6.96% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$62.33
Open:
$62.01
24h Volume:
985.43K
Relative Volume:
0.65
Market Cap:
$8.51B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-8.948
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
-1.16%
1M Performance:
-6.96%
6M Performance:
-6.49%
1Y Performance:
+6.49%
1-Day Range:
$60.89
$62.44
1-Week Range:
$60.89
$64.78
52-Week Range:
$54.30
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.23 | 8.51B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-26 | Upgrade | UBS | Neutral → Buy |
| May-19-26 | Initiated | Citigroup | Buy |
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics to Announce Third Quarter Results on November 4, 2026 - GlobeNewswire Inc.
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Form 4 Cytokinetics Inc: Nancy Wysenski (Director) For: 16 October By Investing.com - Investing.com Canada
195 shares replace a cash retainer for Cytokinetics (CYTK) director Edward M. Kaye. - Stock Titan
A 195-share award brings Harrington's direct Cytokinetics (CYTK) holdings to 22,127 shares. - Stock Titan
Cytokinetics Director Wendell Wierenga Purchases 97 Shares at $63.92 Each - Kalkine Media
Shares replace a cash retainer as Cytokinetics (CYTK) director Henderson receives 352 shares. - Stock Titan
Officer Fady Malik proposes selling 16,386 Cytokinetics (CYTK) shares from option exercises. - Stock Titan
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $113 - Moomoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
29 new hires at Cytokinetics received stock awards. Share awards vest over 3 years; options over 4. - Stock Titan
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - www.marketscreener.com
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - Yahoo Finance
CYTK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
HC Wainwright & Co. reiterates Buy rating on Cytokinetics, $140 price target - TradingView
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth? - Yahoo Finance
BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating - Yahoo Finance
Canada authorizes a drug for adults whose thickened heart muscle blocks blood flow - Stock Titan
Cytokinetics Announces Health Canada Approval of MYQORZO® - GlobeNewswire
CYTK Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
William Blair Initiates Coverage on Cytokinetics With Outperform Rating - Yahoo Finance
William Blair initiates Cytokinetics stock coverage with outperform rating By Investing.com - Investing.com South Africa
William Blair initiates Cytokinetics stock coverage with outperform rating - Investing.com
Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today - Benzinga
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says - marketscreener.com
Cytokinetics (NasdaqGS:CYTK) Stock Forecast & Analyst Predictions - Simply Wall Street
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
UBS cuts Cytokinetics stock price target on valuation, keeps Buy - Investing.com
Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing - Yahoo Finance
A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan
Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance
Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance
Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics presents additional aficamten data from trial - Investing.com
Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan
Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Benzinga
Cytokinetics EVP Fady Malik sells $214,830 in company stock - Investing.com
Form 4 Cytokinetics Inc For: 11 October By Investing.com - Investing.com Nigeria
CYTK6536068 Bond Yield and Price — FINRA:CYTK6536068 - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus
Cytokinetics (CYTK): Company Profile, Stock Price, News, Rankings - Fortune
Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress - Quiver Quantitative
CYTK6536068 Bond Profile: Coupon and Redemption - TradingView
Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics Inc. Advanced Charts | CYTK - Barron's
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 20 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 20 '26 |
Sale |
64.01 |
3,500 |
224,035 |
153,902 |
| Blum Robert I | President & CEO |
Oct 12 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
286,044 |
| Blum Robert I | President & CEO |
Oct 12 '26 |
Sale |
62.88 |
7,500 |
471,600 |
278,544 |
| ROBERT BLUM | Director |
Oct 12 '26 |
Proposed Sale |
62.91 |
22,500 |
1,415,475 |
0 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 06 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 06 '26 |
Sale |
61.38 |
3,500 |
214,830 |
153,902 |
| Blum Robert I | President & CEO |
Sep 28 '26 |
Sale |
65.46 |
7,500 |
490,950 |
278,544 |
| Blum Robert I | President & CEO |
Sep 28 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
286,044 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
2.17%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):